Nascent Biotech Announces Successful Pritumumab In-Vitro Trial Data in Collaborative Covid-19 Treatment Study with Syracuse University

Rhea-AI Summary

Nascent Biotech (OTCQB:NBIO) has reported promising results from its collaboration with Syracuse University, showcasing that its monoclonal antibody, Pritumumab (PTB), effectively blocked 80% of viral entry into cells. This breakthrough allows PTB to advance to laboratory-based animal studies, potentially aiding in COVID-19 treatment. The research highlights PTB's mechanism of action by targeting cell-surface vimentin to inhibit SARS2 entry. The company also launched a Phase I Clinical Trial for Brain Cancer at Hoag Family Cancer Institute, showing commitment to developing treatments for cancers and viral infections.

Positive

• Pritumumab successfully blocked 80% of viral entry into cells.
• Research validates PTB's potential for treating COVID-19.
• Advancement to animal studies for PTB shows progress in development.
• Initiation of Phase I Clinical Trial for Brain Cancer at Hoag Family Cancer Institute.

Negative

• None.

SAN DIEGO, CA / ACCESSWIRE / February 17, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company"), a clinical-stage biotech company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce the publication of strong In-Vitro study results from its research collaboration with Syracuse University.

The data show that Pritumumab ("PTB") successfully blocked 80% of viral entry into cells. Based on these results, PTB will be advanced to laboratory-based animal studies.

Syracuse University researchers, Alison Patteson, assistant professor of physics, and Jennifer Schwarz, associate professor of physics, recently published the study outcomes featuring the viability of certain antibodies to block SARS2 from entering cells by way of cell-surface vimentin, a pathway for the virus to enter the body. The research publication maybe viewed at https://thecollege.syr.edu/news-all/news-from-2021/keeping-sars2-out-of-the-cell/ .

Nascent CEO, Sean Carrick, stated, "The publication by Syracuse University validates the potential for PTB to be used by people experiencing COVID-19 symptoms. The data arising from this research suggest PTB blocks uptake of COVID-19, reducing the spread of the infection in the body. These results may further suggest the efficacy of PTB administered in therapeutic combination with other drugs targeting different pathways."

An article published in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus. This article was instrumental in driving Nascent's investigation into the utility of its anti-vimentin antibodies in battling Viral Infections.

Nascent is currently developing methods to treat Viral Infections along with a traditional vaccine platform. In addition, Nascent recently opened its Phase I Clinical Trial for Brain Cancer at Hoag Family Cancer Institute and Pickup Family Neurosciences Institute Presbyterian, and the Company looks forward to providing additional updates on that process in the near future.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections helping millions of people worldwide. Our products are not commercially available. Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is in Phase I clinical trial for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated. For further information please visit our website www.nascentbiotech.com.

Forward Looking Statement Safe Harbor:

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Sean Carrick
President | CEO
Nascent Biotech, Inc.
772.713.0541 Cell
sean.carrick@nascentbiotech.com

SOURCE: Nascent Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/630116/Nascent-Biotech-Announces-Successful-Pritumumab-In-Vitro-Trial-Data-in-Collaborative-Covid-19-Treatment-Study-with-Syracuse-University

FAQ

What are the recent study results for Pritumumab from Nascent Biotech?

Pritumumab has shown to block 80% of viral entry into cells, as reported in a study conducted with Syracuse University.

What is Pritumumab and its significance in COVID-19 treatment?

Pritumumab (PTB) is a monoclonal antibody that targets cell-surface vimentin to inhibit SARS2 entry, making it a potential treatment for COVID-19.

What clinical trials is Nascent Biotech currently conducting?

Nascent Biotech has launched a Phase I Clinical Trial for Brain Cancer at Hoag Family Cancer Institute.

What institution collaborated with Nascent Biotech for the recent study?

Syracuse University collaborated with Nascent Biotech to conduct the research on Pritumumab.

How might Pritumumab be used in combination therapies?

The research suggests PTB can be administered in combination with other drugs targeting different pathways to enhance therapeutic effects.